C-Reactive Protein Levels at the Midpregnancy Can Predict Gestational Complications
Table 1
Baseline characteristics of the overall cohort.
Overall cohort (n=380)
Demographic and clinical characteristics
Age at enrollment, years (IQR)
34 (31-37)
CR,μg/mL (IQR)
3.25 (1.61-8.07)
Ethnicity
Caucasian, n (%)
342 (90.7)
Latin American, n (%)
20 (5.3)
African, n (%)
6 (1.6)
Indian, n (%)
9 (2.4)
BMI§, kg/m2 (IQR)
21.19 (19.82-26.63)
Underweight, n (%)
22 (9.2)
Normal weight, n (%)
176 (73.6)
Overweight, n (%)
37 (15.5)
Obese, n (%)
10 (4.1)
Weight gain at delivery, kg (IQR)
12 (10-15)
Comorbidities
Thyroid disease, n (%)
28 (7.4)
Hypertension, n (%)
8 (2.1)
PCOS¥, n (%)
7 (1.8)
Coagulation/PLTΦ diseases, n (%)
8 (2.1)
Autoimmune diseases, n (%)
35 (9.2)
GDM#, n (%)
45 (11.9)
Therapy
Thyroid hormone replacement therapy, n (%)
27 (7.1)
Corticosteroid hormone, n (%)
9 (2.4)
Aspirin, n (%)
16 (4.2)
Pregnancy and delivery characteristics
Gestational hypertension, n (%)
5 (1.3)
Premature delivery, n (%)
32 (9.4)
Cesarean delivery, n (%)
177 (50.6)
Urgent Cesarean delivery, n (%)
40 (11.4)
Gestational age at delivery, days (IQR)
275 (270-282)
Overall maternal adverse outcomes
189 (49.7)
Baby characteristics
Baby weight, g (IQR)
3280 (2948.75-3571.25)
Baby length, cm (IQR)
49 (48-50)
Small for gestational age, n (%)
74 (22.4)
Large for gestational age, n (%)
23 (6.9)
Ponderal index (IQR)
2.75 (2.56-2.94)
Macrosomy, n (%)
10 (2.9)
Apgar score
0, n (%)
1 (0.3)
3, n (%)
1 (0.3)
4, n (%)
1 (0.3)
5, n (%)
1 (0.3)
6, n (%)
1 (0.3)
7, n (%)
2 (0.6)
8, n (%)
4 (1.2)
9, n (%)
23 (6.8)
10, n (%)
306 (90)
Resuscitation, n (%)
6 (1.7)
Fetal distress/polyhydramnios, n (%)
3 (0.8)
Overall neonatal adverse outcomes, n (%)
173 (45.5)
Maternal and neonatal adverse outcomes, n (%)
272 (71.6)
Data are expressed as median (interquartile range [IQR], number [n], or percentage [%]). CRP: C-reactive protein. § BMI: body mass index. ¥ PCOS: polycystic ovary syndrome. PLT: platelets. # GDM: gestational diabetes mellitus.
